STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Protecting Youth From Online E-Cigarette Marketing: Findings From a New Study in India,…
Using Satellite Data for Air Quality and Health Applications
The health sector in civil registration: options and methods to increase registration of…
Request for Proposal: New Jersey Drug User Health and Harm Reduction Racial Equity…
Hidden in Plain Sight: Surrogate Marketing of Tobacco Products on Social Media in…
Urban pandemic response: Survey results describing the experiences from twenty-five cities during the…
Policy Brief: Reducing Childhood Lead Poisoning in Indonesia
A content analysis of e-cigarette marketing on social media: Findings from the Tobacco…
Evaluation of two short standardized regimens for the treatment of rifampicin-resistant tuberculosis (STREAM…
Vital Strategies – RESET Alcohol Program